Postpartum Depression — Symptoms, Causes & Treatment | MyMedicPlus

Postpartum depression (PPD) is a major depressive episode with peripartum onset — occurring during pregnancy (antenatal depression, affecting 10-15% of pregnant women) or within 12 months of delivery, with peak incidence in the first 3 months postpartum (DSM-5 peripartum onset specifier). PPD affects 10-15% of new mothers globally — approximately 1 in 7 women — making it the most common complication of childbirth and a leading cause of maternal morbidity. It is critically distinct from the normal 'baby blues' (mild emotional lability, tearfulness, and mood swings in the first 3-7 days postpartum, affecting up to 80% of new mothers) — the baby blues resolve spontaneously within 2 weeks without treatment; PPD persists, worsens, and requires professional assessment and intervention. PPD is also distinct from the rare but severe postpartum psychosis (1 in 500-1,000 deliveries) — a psychiatric emergency characterised by rapid onset (within 2 weeks of delivery) of psychotic symptoms, confusion, and severe mood disturbance requiring immediate inpatient psychiatric admission. Untreated PPD profoundly impairs maternal functioning, mother-infant bonding, breastfeeding success, and quality of life; it has significant long-term developmental consequences for the infant — including elevated rates of emotional, behavioural, and cognitive difficulties. Fathers (5-10%) and partners are also affected by postnatal depression, particularly when the mother has PPD. PPD is highly treatable with early identification, psychotherapy, and antidepressant medication — yet stigma and inadequate postnatal screening mean that fewer than 50% of affected women receive a diagnosis or treatment.

Biological mechanisms: the dramatic and precipitous decline in oestrogen and progesterone in the immediate postpartum period (levels drop from their highest values in pregnancy to near-baseline within 48-72 hours) triggers neurobiological vulnerability in susceptible women — analogous to premenstrual dysphoric disorder (PMDD), PPD represents a hypersensitivity to normal reproductive hormone fluctuations rather than an abnormally large hormonal change. Allopregnanolone (a neurosteroid derived from progesterone that positively modulates GABA-A receptors) fluctuation after delivery disrupts inhibitory GABAergic neurotransmission, contributing to anxiety and mood dysregulation; brexanolone (Zulresso) specifically targets this mechanism. Thyroid dysfunction (postpartum thyroiditis — an autoimmune thyroiditis occurring in 5-10% of new mothers, causing a transient hypothyroid phase at 3-6 months postpartum) can closely mimic PPD in its symptoms — TFTs must be checked in all PPD presentations. Social and psychological risk factors: prior history of depression or PPD (the strongest risk factor — 30-50% recurrence rate with prior PPD history); personal or family psychiatric history (bipolar disorder, schizophrenia, severe anxiety); inadequate social support from partner, family, or community; relationship conflict or domestic violence; a traumatic birth experience (emergency caesarean, perineal injury, instrumental delivery, prolonged labour); breastfeeding difficulties (pain, low supply, rejection by the infant); infant illness or NICU admission; financial stress and housing insecurity; single parenthood; unintended or unwanted pregnancy; and immigration or social isolation. Obstetric risk factors: preterm delivery, birth of a child with illness or disability, perinatal loss, and multiple pregnancy.

Symptoms mirror a major depressive episode: persistent low or depressed mood most of the day, most days; tearfulness and emotional fragility beyond the normal adjustment of new parenthood; anhedonia (inability to experience pleasure — not feeling the expected joy or love when with the baby, which causes profound guilt and shame); fatigue and exhaustion that exceeds what is explained by sleep deprivation and does not improve with rest; sleep disturbance — inability to sleep even when the baby sleeps (hyperarousal and rumination); appetite change (reduced appetite or emotional eating); poor concentration and memory difficulties; feelings of worthlessness, excessive guilt, and self-criticism (feeling like a failure as a mother); and hopelessness or thoughts that the future will not improve. Characteristic PPD-specific features that distinguish it from general depression: persistent feeling of emotional disconnection or detachment from the baby (the expected rush of love not felt — one of the most distressing and shame-inducing symptoms, often not disclosed spontaneously); intrusive, unwanted, ego-dystonic thoughts about harm coming to or being caused to the baby (not intentions or commands — these are characteristic of OCD in the postpartum period, not psychosis; must be specifically distinguished from command hallucinations in postpartum psychosis); fear of being alone with the baby; and excessive, disabling anxiety about the baby's health, feeding, or safety (postpartum anxiety affects 10-15% of new mothers and often accompanies or precedes PPD). Postpartum psychosis (1 in 500-1,000 deliveries — a psychiatric emergency): rapid-onset (within 2 weeks of delivery) confusion, disorientation, hallucinations (auditory, visual), delusions, severe mood swings (mania or severe depression with psychosis), and bizarre behaviour — requires immediate emergency psychiatric inpatient admission; women with bipolar disorder or prior postpartum psychosis are at particularly high risk.

Edinburgh Postnatal Depression Scale (EPDS): the validated and globally recommended 10-item self-report screening questionnaire for PPD — administered routinely at the 6-8 week postnatal check and at 3-6 months postpartum (and antenatally in high-risk women); a score above 12 indicates probable PPD warranting full clinical assessment; a score above 9 warrants follow-up. Critically, EPDS question 10 (assessing thoughts of self-harm or suicidal ideation) must always be reviewed directly by the clinician regardless of total score — a positive answer requires immediate risk assessment and mental health referral. Clinical interview: DSM-5 diagnostic criteria require at least 5 of 9 depressive symptoms (including depressed mood and/or anhedonia as core features) most of the day, nearly every day, for at least 2 weeks, with peripartum onset and causing clinically significant impairment. The PHQ-9 (Patient Health Questionnaire-9) can supplement the EPDS and provides a validated severity rating (mild 5-9, moderate 10-14, moderately severe 15-19, severe 20-27). Blood tests to exclude medical causes contributing to or mimicking PPD: thyroid function tests including TSH and free T4 (postpartum thyroiditis affects 5-10% of new mothers and causes a hypothyroid phase at 3-6 months that closely mimics PPD in symptoms); full blood count (iron-deficiency anaemia from peripartum blood loss is extremely common and exacerbates fatigue and mood symptoms); serum ferritin (iron stores); vitamin D level (deficiency increases depression risk); vitamin B12; and fasting glucose. Postpartum psychosis is a clinical diagnosis based on recognition of rapid-onset psychotic features, confusion, and severe mood disturbance — distinguished from PPD by the presence of hallucinations, delusions, disorientation, and rapid behavioural deterioration within 2 weeks of delivery; all women with any psychotic features require immediate psychiatric assessment.

Mild-moderate PPD: psychotherapy — CBT and Interpersonal Therapy (IPT) are both evidence-based and preferred first-line for breastfeeding mothers. Mindfulness-based CBT programs adapted for the perinatal period. Practical support: parent support groups, home visiting programs, partner and family involvement. Moderate-severe PPD: SSRIs are the pharmacological treatment of choice — sertraline and paroxetine have the most safety data in breastfeeding and transfer minimally into breast milk. Brexanolone (Zulresso) is an IV neuroactive steroid GABA modulator approved specifically for PPD by the FDA in 2019: administered over 60 hours in a monitored healthcare setting with rapid antidepressant response. Postpartum psychosis: emergency admission, antipsychotics, mood stabilizers — lithium is highly effective for prevention in subsequent pregnancies. Regular monitoring of treatment response, early detection of side effects, and ongoing assessment of disease progression are essential components of optimising patient outcomes over the long term. Treatment plans should be proactively reviewed and appropriately adjusted based on clinical response, patient-reported tolerability, changing patient circumstances, and continuously evolving evidence-based clinical guidelines. Meaningful shared decision-making between patients and their healthcare team, incorporating patient values and treatment preferences, consistently improves both treatment adherence and long-term outcomes.

Untreated PPD profoundly impairs mother-infant attachment and bonding — the sensitive period for secure attachment formation is the first year of life, and maternal emotional unavailability from depression disrupts this, reducing breastfeeding initiation and duration, increasing infant insecurity, and impairing cognitive and emotional development. Infants of mothers with untreated PPD have higher rates of emotional and behavioural problems, cognitive and language developmental delays, insecure attachment, and increased risk of depression and anxiety in childhood and adolescence. Maternal suicide is the leading cause of maternal death in the first postnatal year in high-income countries — PPD-associated suicidal ideation is often underreported by mothers who fear stigma or removal of their baby; routine EPDS question 10 assessment is critical. Postpartum psychosis, if unrecognised or inadequately treated, carries serious risks of infanticide and maternal suicide — it requires immediate emergency psychiatric inpatient admission with specialist perinatal psychiatry care; mother and baby units (MBUs) allow continued bonding during inpatient treatment. PPD recurs in 30-50% of subsequent pregnancies in women with a prior episode; women with a history of bipolar disorder or prior postpartum psychosis have a 70-80% risk of recurrence in future pregnancies — a perinatal mental health plan with prophylactic medication (lithium or SSRIs initiated immediately postpartum) dramatically reduces this risk. Partners of women with PPD (5-10% of fathers) also develop postnatal depression, amplifying adverse infant developmental outcomes when both parents are affected.

Women with prior PPD or psychiatric history should have a perinatal mental health plan established in early pregnancy with close monitoring postnatally. Prophylactic antidepressants started immediately after delivery reduce PPD recurrence in high-risk women. Social support (from partner, family, community) is the most protective factor. Ensure adequate sleep through shared infant care; sleep deprivation worsens PPD. Brexanolone may have a role in prevention for high-risk women. Regular EPDS screening at all postnatal contacts identifies cases before they become severe. Sustained lifestyle modifications — maintaining a healthy body weight through balanced diet and regular physical activity, avoiding tobacco smoking, limiting alcohol intake, and managing chronic conditions such as hypertension and diabetes — are foundational strategies for reducing the risk of this condition and its complications. Regular health screening in at-risk populations, rigorous adherence to prescribed preventive medications, and proactive monitoring of established risk factors are equally critical and complementary components of a comprehensive and effective long-term prevention strategy.

Call emergency services or go to A&E immediately if: you are experiencing thoughts of harming yourself or your baby — postpartum psychosis (new onset psychosis with confusion, hallucinations, severe mood swings) is a psychiatric emergency requiring immediate inpatient admission; infanticide risk, while rare, is a serious complication of untreated postpartum psychosis. See your midwife, health visitor, or GP within 24–48 hours if you are in the first 6 weeks postpartum and experiencing: persistent low mood lasting more than 2 weeks beyond the 'baby blues' phase; feeling detached from or unable to bond with your baby; intrusive thoughts about harm to the baby (these are ego-dystonic and not intentions — they are a recognised symptom of PPD and OCD, not psychosis); or inability to sleep even when the baby sleeps. Score yourself on the Edinburgh Postnatal Depression Scale (EPDS): a score above 12 should prompt immediate discussion with your GP or midwife. PPD responds excellently to treatment — early intervention leads to faster recovery and protects your baby's development. Partners, fathers, and co-parents should also watch for low mood, as paternal PPD (5–10%) is common and often unrecognised.